Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy

被引：0
|
作者：
Nermine H. Zakaria
Doaa Hashad
Marwa H. Saied
Neamat Hegazy
Alyaa Elkayal
Eman Tayae
机构：
[1] University of Alexandria,Department of Clinical and Chemical Pathology, Faculty of Medicine
[2] University of Alexandria,Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine
来源：
Human Genomics | / 17卷
关键词：
HER2-positive breast cancer; Genetic variants; NGS; Trastuzumab; Drug resistance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Involvement of microRNAs-449/FASN axis in response to trastuzumab therapy in HER2-positive breast cancer
    Lameirinhas, Ana
    Torres-Ruiz, Sandra
    Garrido-Cano, Iris
    Hernando, Cristina
    Martinez, Maria Teresa
    Rovira, Ana
    Albanell, Joan
    Zazo, Sandra
    Rojo, Federico
    Bermejo, Begona
    Lluch, Ana
    Cejalvo, Juan Miguel
    Tormo, Eduardo
    Eroles, Pilar
    MOLECULAR MEDICINE, 2025, 31 (01)
  • [42] Clinicopathological features among patients with HER2-positive breast cancer with prolonged response to trastuzumab based therapy
    Vaz-Luis, I.
    Seah, D.
    Olson, E.
    Metzger, O.
    Wagle, N.
    Sohl, J.
    Litsas, G.
    Burstein, H.
    Krop, I.
    Winer, E.
    Lin, N. U.
    CANCER RESEARCH, 2012, 72
  • [43] A 10-Gene Signature for Predicting the Response to Neoadjuvant Trastuzumab Therapy in HER2-Positive Breast Cancer
    Jia, Luyao
    Ling, Yuwei
    Li, Kaifu
    Zhang, Lina
    Wang, Yajun
    Kang, Hua
    CLINICAL BREAST CANCER, 2021, 21 (06) : E654 - E664
  • [44] Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy
    Carlos Acevedo-Gadea
    Christos Hatzis
    Gina Chung
    Neal Fishbach
    Kimberly Lezon-Geyda
    Daniel Zelterman
    Michael P. DiGiovanna
    Lyndsay Harris
    Maysa M. Abu-Khalaf
    Breast Cancer Research and Treatment, 2015, 150 : 157 - 167
  • [45] Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy
    Acevedo-Gadea, Carlos
    Hatzis, Christos
    Chung, Gina
    Fishbach, Neal
    Lezon-Geyda, Kimberly
    Zelterman, Daniel
    DiGiovanna, Michael P.
    Harris, Lyndsay
    Abu-Khalaf, Maysa M.
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 150 (01) : 157 - 167
  • [46] Association of Rac1 Expression with Trastuzumab Resistance In HER2-Positive Breast Cancer
    Varol, Umut
    Karaca, Burcak
    Patir, Pusem
    Sener, Alper
    Zekioglu, Osman
    Sanli, Ulus A.
    Uslu, Ruchan
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2013, 23 (04): : 219 - 226
  • [47] KATHERINE: Trastuzumab emtansine vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer
    Mamounas, Eleftherios P.
    Geyer, Charles E., Jr.
    Huang, Chiun-Sheng
    Mano, Max S.
    Loibl, Sibylle
    Untch, Michael
    Wolmark, Norman
    Rastogi, Priya
    Schneeweiss, Andreas
    Redondo, Andres
    Fischer, Hans H.
    Jacot, William
    Conlin, Alison K.
    Arce-Salinas, Claudia
    Wapnir, Irene L.
    Jackisch, Christian
    DiGiovanna, Michael P.
    Fasching, Peter A.
    Crown, John P.
    Wuelfing, Pia
    Shao, Zhimin
    Caremoli, Elena Rota
    Wu, Haiyan
    Lam, Lisa H.
    Tesarowski, David
    Smitt, Melanie
    Douthwaite, Hannah
    Singel, Stina M.
    von Minckwitz, Gunter
    SWISS MEDICAL WEEKLY, 2019, 149 : 13S - 13S
  • [48] Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    Piccart-Gebhart, MJ
    Procter, M
    Leyland-Jones, B
    Goldhirsch, A
    Untch, M
    Smith, I
    Gianni, L
    Baselga, J
    Bell, R
    Jackisch, C
    Cameron, D
    Dowsett, M
    Barrios, CH
    Steger, G
    Huang, CS
    Andersson, M
    Inbar, M
    Lichinitser, M
    Láng, I
    Nitz, U
    Iwata, H
    Thomssen, C
    Lohrisch, C
    Suter, TM
    Ruschoff, J
    Süto, T
    Greatorex, V
    Ward, C
    Straehle, C
    McFadden, E
    Dolci, MS
    Gelber, RD
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16): : 1659 - 1672
  • [49] Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
    Geyer Jr, Charles E.
    Untch, Michael
    Huang, Chiun-Sheng
    Mano, Max S.
    Mamounas, Eleftherios P.
    Wolmark, Norman
    Rastogi, Priya
    Schneeweiss, Andreas
    Redondo, Andres
    Fischer, Hans H.
    D'Hondt, Veronique
    Conlin, Alison K.
    Guarneri, Valentina
    Wapnir, Irene L.
    Jackisch, Christian
    Arce-Salinas, Claudia
    Fasching, Peter A.
    Digiovanna, Michael P.
    Crown, John P.
    Wuelfing, Pia
    Shao, Zhimin
    Caremoli, Elena Rota
    Bonnefoi, Herve R.
    Hennessy, Bryan T.
    Stamatovic, Ljiljana
    Castro-Salguero, Hugo
    Brufsky, Adam M.
    Knott, Adam
    Siddiqui, Asna
    Lambertini, Chiara
    Boulet, Thomas
    Nyawira, Beatrice
    Restuccia, Eleonora
    Loibl, Sibylle
    KATHERINE Study Grp
    NEW ENGLAND JOURNAL OF MEDICINE, 2025,
  • [50] Trastuzumab Use Modest in Patients With HER2-Positive Breast Cancer
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (05) : 339 - 339
12345